Smith & Nephew (LON:SN) Given “Buy” Rating at Shore Capital Group

Smith & Nephew (LON:SN)‘s stock had its “buy” rating restated by investment analysts at Shore Capital Group in a research report issued on Tuesday,Digital Look reports. They presently have a GBX 1,000 price target on the stock. Shore Capital Group’s price objective suggests a potential downside of 12.13% from the company’s previous close.

Other analysts have also recently issued research reports about the company. UBS Group reissued a “neutral” rating and set a GBX 1,300 price objective on shares of Smith & Nephew in a research report on Tuesday, May 5th. Citigroup downgraded Smith & Nephew to a “buy” rating in a research note on Friday, July 10th. Berenberg Bank reiterated a “hold” rating and set a GBX 13 price target on shares of Smith & Nephew in a report on Friday, May 1st. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a GBX 1,400 price target on shares of Smith & Nephew in a research note on Thursday, June 11th. Finally, Jefferies Financial Group restated a “buy” rating and issued a GBX 2,760 price objective on shares of Smith & Nephew in a report on Thursday, May 21st. Four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of GBX 1,340.11.

Smith & Nephew Stock Down 1.1%

Smith & Nephew stock opened at GBX 1,138 on Tuesday. The company has a debt-to-equity ratio of 62.90, a quick ratio of 0.84 and a current ratio of 2.57. The stock has a market cap of £12.48 billion, a PE ratio of 40.97, a P/E/G ratio of 0.46 and a beta of 0.68. The firm’s 50 day moving average is GBX 1,128.38 and its two-hundred day moving average is GBX 1,200.99.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.